IDXX
Idexx Laboratories
$596.54
▲ 1.1%Updated Aug 7, 11:30 AM ET
IDXX at a glance — five pillars scored 0–100 from real filed financials.
Overall: Favorable · 65/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 8.1% over the last 12 months
Market Cap
$44.00B
P/E
43x
Forward P/E (est.)
34.24x
ROE
70.9%
Revenue Growth
13.1%
EPS Growth
25.6%
Profit Margin
24.6%
FCF Yield
1.9%
Debt / Equity
0.53x
ROIC
54.0%
Interest Coverage
32.71x
Current Ratio
1.12x
Dividend Yield
—
Implied Growth (rev. DCF)
6.4%
Rating Score
65/100
Idexx Laboratories (IDXX) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $44.00B.
In its latest reported year it generated about $4.30B in revenue and $1.06B in net profit.
Our model rates IDXX Favorable (65/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
60.9% average over the last 3 years
±2.2 pts around 58.2% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 9 of 9 years
54.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what IDXX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. IDXX trades near $596.54, around its 50-day average ($555.90) and 200-day average ($628.05). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 50 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. IDXX's is $17.47 (~2.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month IDXX found buyers near $518.55 (support) and sellers near $581.47 (resistance); its 52-week range is $506.91–$769.98. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.2× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
7.6%
Revenue moved from $1.78B in 2016 to $4.30B in 2025, a 10.3% compound annual growth rate. The most recent year grew a steady 13.1% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
61.8%
Operating Margin
31.6%
Net Margin
24.6%
ROE
70.9%
Idexx Laboratories keeps about 24.6% of each sales dollar as net profit, with a 61.8% gross margin and 31.6% operating margin. Return on equity is 70.9% and return on invested capital about 54.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$450.00M
Net Debt
$249.47M
Net Debt / EBITDA
0.18x
Debt / Equity
0.53x
Leverage: debt-to-equity is 0.5x, and operating profit covers interest about 32.7x, with a current ratio of 1.1x. That is a moderate, manageable debt load for most businesses. It carries roughly $450.00M of total debt against $200.53M of cash.
Operating CF
$1.18B
Free Cash Flow
$1.06B
FCF Margin
24.6%
In the latest year Idexx Laboratories produced about $1.18B of operating cash flow and $1.06B of free cash flow after capital spending. That is a free-cash-flow yield of about 1.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
43x
P/S
10.51x
P/B
35.03x
EV / EBITDA
—
IDXX trades at 43.0x trailing earnings (about 34.2x on estimated forward earnings), 10.5x sales, and 35.0x book value. Reverse-engineering today's price implies the market expects roughly 6.4% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$381.73
Current price
$596.54
Starting FCF (latest 10-K)
$1.06B
Growth, years 1–5
13.1%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where IDXX sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How IDXX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), IDXX ranks #19 of 324 by our overall rating. It trades at a premium versus the sector on earnings (43x P/E vs. 27.3x median) with a higher return on equity (70.9% vs. 14.1%) and faster revenue growth (13.1% vs. 7.6%).
P/E vs sector
43x
median 27.3x
ROE vs sector
70.9%
median 14.1%
Growth vs sector
13.1%
median 7.6%
Sector rank
#19
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $596.54 today · expected CAGR 3% – 14%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.86B | $5.50B | $6.21B | $7.02B | $7.93B |
| Net income | $1.22B | $1.37B | $1.55B | $1.75B | $1.98B |
| EPS | $16.48 | $18.63 | $21.05 | $23.78 | $26.88 |
| Share price (low) | $428.56 | $484.27 | $547.23 | $618.37 | $698.76 |
| Share price (high) | $708.77 | $800.91 | $905.03 | $1,022.69 | $1,155.63 |
| CAGR (low–high) | -28% / 19% | -10% / 16% | -3% / 15% | 1% / 14% | 3% / 14% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for IDXX:
- Revenue is growing 13.1% a year, a sign of real demand.
- High net margins (24.6%) point to pricing power or efficiency.
- Strong return on equity (70.9%) shows capital is put to work well.
- Our model's overall read is Favorable (65/100).
The case against IDXX:
- A rich 43.0x earnings multiple prices in a lot of growth.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 43.0x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Idexx Laboratories is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 43.0x earnings, which our model scores Favorable (65/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 22 Wall Street analysts covering IDXX recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
IDXX's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
IDXX — frequently asked questions
Is IDXX a good stock to buy?
We don't give buy or sell advice. Our model rates Idexx Laboratories Favorable (65/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is IDXX's rating on The Stocks School?
Idexx Laboratories currently scores 65/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does IDXX's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Idexx Laboratories's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for IDXX calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this IDXX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell IDXX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.